Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 20Nivolumab 10Cyclophosphamide 10atezolizumab 6Specimen Handling 6fludarabine 5Magnetic Resonance Spectroscopy 5cabozantinib 4Ipilimumab 4Bevacizumab 4lenvatinib 3X-Rays 3Trastuzumab 3Paclitaxel 3Oxaliplatin 3Immunoglobulin G 3Fluorodeoxyglucose F18 3ulixertinib 2sargramostim 2poly ICLC 2epacadostat 2enzalutamide 2durvalumab 2cemiplimab 2budigalimab 2avelumab 2aldesleukin 2aflibercept 2Sirolimus 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × cyclopropapyrroloindole × Gynecologic × Clear all
NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3 Recruiting
200 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡